# Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f

> FDA guidance document: Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry. Issue date: October 17, 2022. Get complete insights and analysis.

---

## Details

- Title: Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2022-10-17
- Last Changed: 2025-02-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0286 ">FDA-2022-D-0286 </a>

## Related Documents

- [Drug Master Files Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/drug-master-files-guidance-for-industry/7dfd5140-3156-43f2-bdb9-d23ad597311c)
- [QTc Information in Human Prescription Drug and Biological Product Labeling: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/qtc-information-in-human-prescription-drug-and-biological-product-labeling-draft-guidance-for-industry/31125149-7d83-4062-9793-55cba93d1ee0)
- [Considerations for Rescinding Breakthrough Therapy Designation](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-rescinding-breakthrough-therapy-designation/adc0ae37-722c-4b21-90ea-5a2087f771f0)